GlassScriptPhysician profile
Russell Lee Silverstein
NPI 1063483865
$203,770.04
in general payments reported to CMS, 2019-2025
32 companies · $16K in 2025
The $16K reported for 2025 was more than what 96% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,727 · 2020: $2,141 · 2021: $2,988 · 2022: $57K · 2023: $82K · 2024: $41K · 2025: $16K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $51K · Honoraria: $46K · Travel and Lodging: $32K · Food and Beverage: $8,855 · Consulting Fee: $2,600 · Gift: $40.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $50,670.00 |
| Honoraria | $46,175.00 |
| Travel and Lodging | $31,532.23 |
| Food and Beverage | $8,855.45 |
| Consulting Fee | $2,600.00 |
| Gift | $40.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $65,862.39 | 2020-2025 | Acthar |
| Calliditas Therapeutics US INC. | $56,709.21 | 2022-2025 | Tarpeyo |
| Travere Therapeutics, INC. | $23,008.61 | 2022-2024 | |
| Glaxosmithkline, LLC. | $17,562.93 | 2020-2024 | Benlysta |
| Ani Pharmaceuticals, INC. | $17,311.74 | 2022-2024 | Purified Cortrophin Gel |
| Astrazeneca Pharmaceuticals LP | $14,191.53 | 2019-2025 | Farxiga, Lokelma |
| Horizon Therapeutics Plc | $2,211.57 | 2019-2023 | Krystexxa |
| Akebia Therapeutics INC | $1,725.92 | 2019-2022 | |
| Fresenius USA Marketing, INC. | $706.46 | 2019-2025 | Velphoro, Velphoro |
| Bayer Healthcare Pharmaceuticals INC. | $626.89 | 2021-2025 | |
| Amgen INC. | $492.23 | 2019-2025 | Tavneos, Krystexxa |
| Otsuka America Pharmaceutical, INC. | $455.15 | 2019-2025 | Jynarque |
| Alexion Pharmaceuticals, INC. | $422.16 | 2019-2025 | Ultomiris |
| Vifor Pharma, INC. | $370.93 | 2019-2024 | Veltassa |
| Aurinia Pharma U.S., INC. | $332.43 | 2021-2025 | Lupkynis |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $254.78 | 2019 | |
| Novartis Pharmaceuticals Corporation | $217.03 | 2023-2025 | |
| Ardelyx, INC. | $208.11 | 2024-2025 | Ibsrela |
| Boehringer Ingelheim Pharmaceuticals, INC. | $185.79 | 2024-2025 | Jardiance |
| Novo Nordisk INC | $184.71 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Mallinckrodt Enterprises LLC | $157.21 | 2019 | |
| Opko Pharmaceuticals, LLC | $116.41 | 2019-2025 | Rayaldee |
| Genentech USA, INC. | $115.77 | 2019-2020 | |
| Cormedix INC. | $70.28 | 2024 | Defencath |
| Recor Medical INC | $60.62 | 2024-2025 | Paradise Ultrasound Renal Denervation System, Paradise Renal Denervation System |
| Amarin Pharma, INC. | $48.82 | 2020-2021 | |
| Alnylam Pharmaceuticals INC. | $48.06 | 2019-2024 | Givlaari |
| Kyowa Kirin, INC. | $39.28 | 2025 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $24.57 | 2025 | |
| Ultragenyx Pharmaceutical INC. | $17.20 | 2020 | |
| Apellis Pharmaceuticals, INC. | $16.80 | 2025 | Empaveli |
| Chiesi USA, INC. | $14.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Russell Silverstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.